{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-007674","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.245288+00:00","generated_at":"2026-06-06T23:46:03.018610+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inovio shareholders approve reverse stock split at ratios from 1:10 to 1:50","bullets":["146,265,973 shares (53.6%) present; reverse split approved with 96,534,629 For vs 48,857,255 Against.","Board authorized to implement split at any time within one year of Jan 12, 2024 special meeting.","Split ratio range 1-for-10 to 1-for-50, exact ratio to be determined by Board later.","Adjournment proposal also approved (106,842,257 For) to allow additional solicitation if needed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-007674","json":"https://secwatch.observer/filing/0001193125-24-007674.json","markdown":"https://secwatch.observer/filing/0001193125-24-007674.md","text":"https://secwatch.observer/filing/0001193125-24-007674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524007674/0001193125-24-007674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524007674/d722280d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:46:03.018610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31a7979e086416181cfa1995f28d0d22dbe9556d","claim":"INOVIO PHARMACEUTICALS, INC. shareholders approved Adjournment Proposal at the 2024-01-12 meeting.","evidence_excerpt":"The votes were cast as follows: For Against Abstain 106,842,257 37,097,854 2,325,862 The Adjournment Proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524007674/0001193125-24-007674-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-12"}],"fact_type":"shareholder_vote"},{"claim_id":"348037bb58615fd8e92b75fa310d4f2d6f941454","claim":"INOVIO PHARMACEUTICALS, INC. shareholders approved Reverse Stock Split Proposal at the 2024-01-12 meeting.","evidence_excerpt":"The votes were cast as follows: For Against Abstain 96,534,629 48,857,255 874,089 The Reverse Stock Split Proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524007674/0001193125-24-007674-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}